Natural Capsules Limited concluded its 33rd Annual General Meeting on August 12, 2026, approving key governance resolutions including the reappointment of directors and authorization of related party transactions.

The meeting was conducted through video conferencing from the company’s registered office in Bengaluru. Independent Director Tekkar Yashwanth Prabhu chaired the proceedings, which began at 12:10 pm after confirming the presence of a quorum comprising 34 members.

Key Resolutions Approved

Shareholders transacted six business items during the meeting. The ordinary business included the adoption of audited consolidated and standalone financial statements for the fiscal year ended March 31, 2026.

The board also sought approval for the following governance matters:

• Reappointment of Mrs. Jyoti Mundra as a director retiring by rotation.
• Reappointment of Mr. Laxminarayan Moondra as a director retiring by rotation.
• Reappointment of Mr. Laxminarayan Moondra as Whole Time Director for a three-year term with revised remuneration (Special Resolution).
• Approval of related party transactions with subsidiary Natural Biogenex Private Limited.
• Revision in remuneration for Mr. Shrey Mundra, General Manager – Marketing.

Voting Process

Pursuant to Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company provided remote e-voting facilities from August 8 to August 11, 2026. Members attending the virtual meeting who had not voted remotely were given an additional 15-minute window to cast their votes electronically via the NSDL portal during the AGM.

Mr. Deepak Sadhu of Deepak Sadhu & Co served as the scrutinizer for the voting process. The final results will be submitted to stock exchanges separately upon receipt of the scrutinizer’s report.

Natural Capsules Limited has expanded the agenda for its upcoming Board of Directors meeting on August 12, 2026, to include a significant capital-raising initiative. In addition to approving the unaudited consolidated and standalone financial results for the quarter ended June 30, 2026 (Q1FY26), the Board will evaluate a proposal to raise funds through the preferential issue of equity shares, convertibles, or other eligible securities. This move signals the company’s intent to strengthen its capital base, subject to necessary regulatory and shareholder approvals.

The company notified the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE) on August 9, 2026, regarding this addition to the agenda previously intimated on August 4, 2026. The proposed fund raising is contingent upon obtaining all required regulatory and statutory approvals, as well as explicit approval from the company’s shareholders. The specific amount to be raised or the target investors have not been disclosed in this filing.

Regulatory Compliance and Trading Window

In adherence to the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company’s internal Code of Conduct for the Prevention of Insider Trading, the trading window for dealing in the equity shares of Natural Capsules Limited remains closed. This restriction applies to all Designated Persons and their immediate relatives. The window will remain shut from July 1, 2026, until 48 hours after the declaration of the financial results for the quarter ended June 30, 2026.

Key Agenda Items

The Board meeting on August 12, 2026, focuses on two primary areas:

Akshay Dutta, Company Secretary and Compliance Officer of Natural Capsules Limited, signed the communication to the exchanges. The filing underscores the procedural steps required before any capital infusion can proceed, highlighting the need for shareholder consent alongside regulatory clearances.